ACADIA Pharmaceuticals, a biopharmaceutical company, completed the acquisition of CerSci Therapeutics, a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, for $939m. Under the terms of the agreement, ACADIA acquired all of the outstanding shares of CerSci for $52m, primarily in ACADIA stock. CerSci shareholders may also receive up to $887m in development, commercialization, and sales milestones in addition to tiered royalties in the mid-single digits based on annual net sales. "There is an urgent need for new approaches to treat pain without causing addiction. We are excited by the potential clinical utility of this program across multiple pain modalities due to its novel non-opioid mechanism of action. By acquiring CerSci, ACADIA is further strengthening our development pipeline for long-term growth in central nervous system disorders," Steve Davis, ACADIA CEO.